Zusammenfassung
Die Rolle der Chirurgie per se und die Art des chirurgischen Eingriffes im Rahmen multimodaler Therapiekonzepte werden für das maligne Pleuramesotheliom kontrovers diskutiert. Die Indikationstellung zur extrapleuralen Pneumonektomie oder zur radikalen Pleurektomie ist nicht nur abhängig vom kardiopulmonalen Status des Patienten, Tumorstadium und dem intraoperativen Befund, sondern wird vielmehr von den Präferenzen, Erfahrungen und der Philosophie des Chirurgen entscheidend mit beeinflusst. Die vorliegende Arbeit soll die extrapleurale Pneumonektomie und radikale Pleurektomie in Bezug auf Operationstechnik, Morbidität, Mortalität und Überleben vergleichen.
Abstract
The role of surgical resection per se and the type of surgery in the management of multimodality treated malignant pleural mesothelioma remains controversial. Patient selection for either extrapleural pneumonectomy or radical pleurectomy depends not only on the cardiopulmonary status of the patient, tumor stage and intraoperative findings but is also strongly influenced by surgeons’ preference, experience and philosophy. The aim of this review is to compare extrapleural pneumonectomy and radical pleurectomy with regard to surgical technique, morbidity, mortality and survival.
Literatur
Ambrogi V, Mineo D, Gatti A et al (2009) Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma. J Surg Oncol 100(3):199–204
Baldini EH, Recht A, Strauss GM et al (1997) Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63:334–338
Bölükbas S, Eberlein M, Schirren J (2012) Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma. J Thorac Oncol 7(5):900–905
Bölükbas S, Eberlein M, Schirren J (2012) Video-atlas of radical pleurectomy for malignant pleural mesothelioma. Ann Cardiothorac Surg. doi:10.3978/j.issn.2225-319X.2012.10.06
Bölükbas S, Manegold C, Eberlein M et al (2011) Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with Cisplatin/Permetrexed and radiotherapy. Lung Cancer 71(1):75–81
Branscheid D, Krysa S, Bauer E et al (1991) Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Eur J Cardiothorac Surg 5:466–472
Cao C, Tian D, Manganas C et al (2012) Systematic review of trimodality therapy for patients with malignant pleural mesothelioma. Ann Cardiothorac Surg 1(4):428–437. doi:10.3978/j.issn.2225-319X.2012.11.07
Perrot M de, Feld R, Cho BCJ et al (2009) Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 27:1413–1418
Flores RM, Pass HI, Seshan VE et al (2008) Extrapleural pneumonectomy versus pleurectomy in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135:620–626
Friedberg JS, Culligan MJ, Mick R et al (2012) Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg 93:1658–1667
Friedberg JS, Mick R, Culligan M et al (2011) Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma. Ann Thorac Surg 91:1738–1745
Jassem J, Ramlau R, Santoro A et al (2008) Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26:1698–1704
Krug LM, Pass HI, Rusch VW et al (2009) Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27:3007–3013
Lang-Lazdunski L, Bille A, Lal R et al (2012) Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol 7(4):737–743
Manegold C, Symanowski J, Gatzemeier U et al (2005) Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 16:923–927
Martini N, Bains MS, Beattie EJ Jr (1975) Indications for pleurectomy in malignant effusion. Cancer 35(3):734–738
Mollberg NM, Vigneswaran Y, Kindler HL et al (2012) Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg 94:1086–1092
Ramalingam SS, Belani CP (2008) Recent advances in the treatment of malignant pleural mesothelioma. J Thorac Oncol 3(9):1056–1064
Rice D, Rusch V, Pass H et al (2011) Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 6(8):1304–1312
Ried M, Potzger T, Braune N et al (2012) Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience. Eur J Cardiothorac Surg (10.1093/ejcts/ezs418)
Rusch VW, Rosenzweig K, Venkatraman E et al (2001) A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122:788
Rusch VW, Venkatraman ES (1999) Important prognostic factors in patients with malignant pleural mesothelioma managed surgically. Ann Thorac Surg 68:1799–1804
Schipper PH, Nichols FC, Thomse KM et al (2008) Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 85:257–264
Sugarbaker DJ (2006) Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol 1(2):175–176
Sugarbaker DJ, Flores RM, Jaklitsch MT et al (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54
Treasure T, Internullo E, Fiorentino F et al (2011) A survey of opinions and beliefs concerning surgery for malignant pleural mesothelioma amongst 802 members of the European Association for Cardio-Thoracic Surgery (EACTS), the European Society of Thoracic Surgeons (ESTS) and the Society of Thoracic Surgeons (STS). Interact Cardiovasc Thorac Surg 12:341–346
Tilleman TR, Richards WG, Zellos L et al (2009) Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 138:405–411
Tselis N, Ferentinos K, Kolotas C et al (2011) Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies. J Thorac Oncol 6(3):545–552
Utley M, Fiorentino F, Treasure T (2010) Obtaining an upper estimate of the survival benefit associated with surgery for mesothelioma. Eur J Cardiothorac Surg 38:241–244
Weder W, Stahel RA, Bernhard J et al (2007) Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Onc 18:1196–1202
Interessenkonflikt
Der korrespondierende Autor gibt für sich und seinen Koautor an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bölükbas, S., Schirren, J. Malignes Pleuramesotheliom. Chirurg 84, 487–491 (2013). https://doi.org/10.1007/s00104-012-2432-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00104-012-2432-5
Schlüsselwörter
- Malignes Pleuramesotheliom
- Radikale Pleurektomie
- Extrapleurale Pneumonektomie
- Operationstechnik
- Behandlungsergebnis